10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction

Study (n=1498) found rates of patient-oriented composite endpoint and device-oriented composite endpoint were significantly reduced in everolimus stent group (32.4% vs 38.0% [HR:0.81; 95%CI:0.68-0.96; p=0.013] and 13.6% vs 18.4% [HR:0.72; 95%CI:0.55-0.93; p=0.012] respectively).

Journal of the American College of Cardiology